Gilead Sciences Inc (GILD) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$75.38 after a previous close of US$75.23. During the day the price has varied from a low of USD75.31 to a high of USD76.74. The latest price was USD76.615 (25 minute delay). Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
Gilead Sciences's shares were split on a 2:1 basis on 28 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
| Open | US$75.38 |
|---|---|
| High | US$76.74 |
| Low | US$75.31 |
| Close | US$76.615 |
| Previous close | US$75.23 |
| Change | US$1.385 |
| Change % | 1.841% |
| Volume | 9,642,136 |
| 52-week range | US$72.5394 - US$86.7523 |
|---|---|
| 50-day moving average | US$76.6898 |
| 200-day moving average | US$78.6239 |
| Target price | US$89.76 |
| PE ratio | 16.1413 |
| Dividend yield | US$2.98 (3.98%) |
| Earnings per share (TTM) | US$4.67 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $76.615
| 1 week (2023-11-21) | 2.58% |
|---|---|
| 1 month (2023-10-30) | -1.49% |
| 3 months (2023-08-30) | -1.35% |
| 6 months (2023-05-30) | 0.37% |
| 1 year (2022-11-30) | -12.77% |
|---|---|
| 2 years (2021-11-30) | 11.15% |
| 3 years (2020-12-01) | 25.35% |
| 5 years (2018-11-30) | 6.50% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Gilead Sciences shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.716. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$11.7 billion (£9.3 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$72.5394 up to US$86.7523. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.336. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
| Revenue TTM | US$27.4 billion |
|---|---|
| Operating margin TTM | 38.51% |
| Gross profit TTM | US$21.6 billion |
| Return on assets TTM | 9.21% |
| Return on equity TTM | 26.92% |
| Profit margin | 21.45% |
| Book value | 17.894 |
| Market capitalisation | US$93.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 42.92% of net profits
Recently Gilead Sciences has paid out, on average, around 42.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.98% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 3.98% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.98 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 28 December 2023. The latest dividend was paid out to all shareholders who bought their shares by 14 December 2023 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.15 |
|---|---|
| Total ESG percentile | 30.98 |
| Environmental score | 0.53 |
| Environmental score percentile | 2 |
| Social score | 12.97 |
| Social score percentile | 2 |
| Governance score | 7.65 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
